Study of Epratuzumab in Systemic Lupus Erythematosus

Completed · Phase 2

Conditions studied: Systemic Lupus Erythematosus

In brief

Epratuzumab is an investigational antibody designed to help treat Systemic Lupus Erythematosus (SLE). The purpose of the study is to obtain additional long-term information regarding the safety and efficacy of continued maintenance-cycle administrations of Epratuzumab.

Key facts

Study ID

NCT00383513

Run by

UCB Pharma

People needed

29

Starts

2006-06-01

Expected to finish

2012-01-01

Last updated by the study team

2012-07-12

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Must have participated in SL0003 or SL0004 and benefitted from participation in those studies

You may not qualify if…

• Development of toxicity to epratuzumab
• Significant protocol deviations during the SL0003 or SL0004 studies
• Evidence of significant infection

Where it is running

• Study site — Birmingham, Alabama, United States
• Study site — Tucson, Arizona, United States
• Study site — Los Angeles, California, United States
• Study site — Upland, California, United States
• Study site — Colorado Springs, Colorado, United States
• Study site — Denver, Colorado, United States
• Study site — Washington D.C., District of Columbia, United States
• Study site — Baltimore, Maryland, United States
• Study site — Durham, North Carolina, United States
• Study site — Tulsa, Oklahoma, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.